Comprehensive Solutions to Explore Mechanisms of Drug-Induced Liver Injury (DILI)
Hepatotoxicity is one of the major causes of failure during drug development and removal of approved drugs from the market. As a leader in toxicology and safety screening, Eurofins Discovery offers comprehensive solutions for assessing hepatotoxicity early in drug discovery. Our experts provide project-specific guidance and validated assays to help investigate DILI, including in vitro cell-based toxicity assays using human primary cells or immortalized hepatoma cells, 3D liver spheroids, reactive metabolic formation, mitochondrial impairment, cholestasis, phospholipidosis, lysomal trapping, liver transporter assays, and more.
In vitro Hepatotoxicity Testing Platform Highlights
- Detect unwanted adverse liver effects with specially designed assays
- Rapid compound profiling with cost-effective high-throughput screening
- In-depth assessment for DILI potential with detailed mechanistic assays
- Toxicology experts to help navigate project-specific adverse liver effects
Delivering High-quality Solutions for Your Hepatotoxicity Testing Needs
Whether you need early-stage hepatotoxicity testing or a deep dive into DILI mechanisms, Eurofins Discovery has effective solutions for assessing the potential hepatotoxicity of drug candidates. Reference the table below to identify the service that will meet your hepatotoxicity testing needs or contact us for personalized support for your project.
| Category | Objective | Assays | |
|---|---|---|---|
| Hepatotoxicity – 2D | Cell viability in HepG2 and Primary Hepatocytes | Study drug induced hepatotoxicity with validated cell viability assays using HepG2 cells or primary hepatocytes from human, rat, mouse, with other species and testing conditions available upon request. | Cell Viability (HepG2, 48-hour, CellTiter-Glo) |
| Cell Viability (Human Primary Hepatocytes, 48-hour, CellTiter-Glo) | |||
| Cell Viability (Rat Primary Hepatocytes, 48-hour, CellTiter-Glo) | |||
| Cell Viability (Mouse Primary Hepatocytes, 48-hour, CellTiter-Glo) | |||
| Cytotoxicity (human primary hepatocytes, 48-hour, LDH-Glo) | |||
| Hepatotoxicity – 3D | Hepatotoxicity in 3D Human Spheroids | Explore hepatotoxicity in 3D spheroids. Primary human hepatocytes cultured in 3D spheroids maintain long-term, hepatocyte-specific functions, providing a more physiologically relevant test system. | Hepatotoxicity (3D spheroids, human primary hepatocytes, 7-day, CellTiter-Glo) |
| Hepatotoxicity IC50 (3D spheroids, human primary hepatocytes, 7-day, CellTiter-Glo) | |||
| Mitochondrial Impairment | Mitochondrial Toxicity | The mitochondrial Glu/Gal assay provides an ideal screening assay to detect effects of drug-induced mitochondrial impairment versus overt cellular toxicity. | Mitochondrial Toxicity Panel (CellTiter-Glo) |
| Reactive Metabolites | Reactive Metabolite Formation | Evaluate the formation of reactive metabolites for de-risking lead therapeutic compounds or troubleshoot adverse events in late-stage programs with our newly validated qualitative in vitro cocktail method. | Reactive metabolite (cocktail trapping (GSH, NAC, SCA, MeA), liver microsomes, human) |
| Phospholipiosis | Drug-induced Phospholipidosis | A rapid image-based high content analysis (HCA) assay to assess drug-induced phospholipidosis in HepG2 cells. | Phospholipidosis (HepG2, HCA) |
| Hepatic Cellular Markers | High Content Analysis in HepG2 | High-throughput assays in live HepG2 cells measuring sensitive cellular parameters such as mitochondrial membrane potential, intracellular free calcium, membrane permeability and cell proliferation. | Cytotoxicity (HepG2; 5 endpoints; HCA) |
| Cellular Stress Response in Primary Human Hepatocytes | Assess hepatotoxicity potential of drugs with multiplexed technologies in primary human hepatocytes, measuring critical markers of liver toxicity such as cell viability, reactive oxygen species (ROS), mitochondrial membrane potential (MMP), HSP27, and apoptosis. | Cellular Stress (HPH; Cell Viability; HSP27; Apoptosis) | |
| Cytotoxicity (HPH; Cell Viability; ROS; MMP) | |||
| Cytotoxicity (HPH; Cell Viability; Apoptosis) | |||
| Nuclear Receptor Activation | Investigate drug interaction with nuclear receptors known to play a role in liver injury. | FXR Human Liver X Receptor-Like NHR Functional Agonist & Antagonist Coactivator LeadHunter Assay | |
| Liver Drug Transporters | Liver Transporter Assays | Liver transporters may play an important role in the uptake and efflux of drugs in the liver. Investigate liver drug-transporter interactions in OATPB1, OATP1B3, BSEP, transporter panels, and more, as recommended by regulatory guidelines. | OATP1B1 Substrate Assessment (OATP1B1-CHO) |
| OATP1B3 Substrate Assessment (OATP1B3-CHO) | |||
| BSEP inhibition (BSEP-HEK membrane vesicles, taurocholic acid substrate) | |||
| DILI Panels | DILI Screening and Mechanistic Panels | DILI testing services available in a high-throughput screening panel and a broader, more detailed mechanistic panel to improve the detection of potential hepatotoxicity. Our DILI mechanistic panel measures 12 endpoints providing a detailed assessment of known indicators of DILI. | Drug-Induced Liver Injury (DILI) Screening Panel |
| Drug-Induced Liver Injury (DILI) Mechanistic Panel – please contact client services for assistance. |
more hepatotoxicity options available at eurofinsdiscovery.com
